Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Safety and Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naïve Patients With Cystinosis

NCT01744782 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01744782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01744782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Safety and Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naïve Patients With Cystinosis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
December 20, 2012
Completion date
December 13, 2016
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cystinosis